SARS-CoV-2 (COVID-19) ORF8 Antibody

blue ice or RT

Anti-SARS-CoV-2 (COVID-19) ORF8 antibody (9287) was raised against a peptide corresponding to 14 amino acids near carboxyl terminus of SARS-CoV-2 (COVID-19) ORF8 protein.

The immunogen is located within the last 50 amino acids of the SARS-CoV-2 (COVID-19) ORF8 protein.

ORF8 Antibody is predicted to not cross-react with other coronavirus family members.

SARS-CoV-2 (COVID-19) ORF8 Antibody is affinity chromatography purified via peptide column.

IgG

SARS-CoV-2 (COVID-19) ORF8 antibody is supplied in PBS containing 0.02% sodium azide.

SARS-CoV-2 (COVID-19) ORF8 antibody can be stored at 4˚ C for three months and -20˚ C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.

P0DTC8

43740577

ORF8

Severe acute respiratory syndrome coronavirus 2

Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). SARS-CoV-2 virus proteins include structural proteins, non-structural proteins and accessory factors. The structure of SARS-CoV-2 consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. SARS-CoV-2 non-structural protein is ORF1ab that consists of 16 proteins (nsp1-nsp16), while accessory factors include ORF3a, ORF3b, ORF6, ORF7a, ORF7b, ORF8, ORF9b, ORF9c and ORF10. ORF8 may play a role in modulating host immune response (Probable). May play a role in blocking host IL17 cytokine by its interaction with host IL17RA (3).

Hui et al. Int J Infect Dis. 2020; 91:264-266.

Figure 1 Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) ORF8 in COVID-19 Patient Lung
Immunohistochemical analysis of paraffin-embedded COVID-19 patient lung tissue using anti- SARS-CoV-2 (COVID-19) ORF8 antibody (9287, 0.1 μ g/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚ C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. Strong signal of SARS-COV-2 ORF8 protein was observed in macrophages of COVID-19 patient lung, but not in non-COVID-19 patient lung.

Figure 3 Western Blot Validation with SARS-CoV-2 (COVID-19) ORF8 Protein
Loading: 30 ng per lane of SARS-CoV-2 (COVID-19) ORF8 recombinant protein (10-436).Antibodies: SARS-CoV-2 (COVID-19) ORF8, 9287, 1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.Lane 1: 1 μ g/mL and Lane 2: 2 μ g/mL